Immunotherapy plus targeted drug shows promise in rare aggressive lung cancer
A phase 2 trial reports that camrelizumab plus famitinib produced tumor shrinkage in 42.9 percent of patients with advanced pulmonary ...
Tag: CAPSTONE trial
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development